PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6

• Saulius K. Girnius,
• Joshua Richter,
• Roger M. Lyons,
• Kimberly Bogard,
• Sudhir Manda,
• Ruemu E. Birhiray,
• Habte A. Yimer,
• Kim Tran,
• Suman Kambhampati,
• Jyoti Arora,
• Stephen Noga,
• Robert Rifkin

Affiliations

Saulius K. Girnius

1 Trihealth Cancer Institute, Cincinnati, OH, United States

Joshua Richter

2 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States

Roger M. Lyons

3 Texas Oncology/US Oncology Research, San Antonio, TX, United States

Kimberly Bogard

4 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States

Sudhir Manda

5 Arizona Oncology/US Oncology Research, Tucson, AZ, United States

Ruemu E. Birhiray

6 Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN, United States

Habte A. Yimer

7 Texas Oncology/US Oncology Research, Tyler, TX, United States

Kim Tran

4 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States

Suman Kambhampati

8 Kansas City Veterans Affairs Medical Center, Kansas City, MO, United States

Jyoti Arora

9 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States

Stephen Noga

9 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States

Robert Rifkin

10 Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO, United States